Description
Drugs targeting the incretin system, such as DPP-4 inhibitors (e.g., vildagliptin, sitagliptin) and GLP-1 analogues, have emerged as effective, safe options for type 2 diabetes management. DPP-4 inhibitors improve glycemic control by enhancing insulin secretion and suppressing glucagon release, with minimal risk of hypoglycemia and neutral effects on body weight. Recommended as second-line therapy with metformin or sulfonylureas, they can also serve as first-line treatment for patients intolerant to metformin. A recent 12‑month outpatient study evaluated vildagliptin monotherapy in newly diagnosed, drug‑naïve patients, demonstrating its potential as an effective initial therapy for type 2 diabetes.